In 2020, Ashley Harms, Ph.D., and University of Alabama at Birmingham colleagues published an Acta Neuropathologica study that used a mouse model to show that the alpha-synuclein pathology from ...
HONOLULU — A novel “moderate-affinity iron chaperone” known as ATH434 (Alterity Therapeutics) may slow disease progression in patients with multiple system atrophy (MSA), new research suggested. The ...
Stockhead on MSN
Alterity in spotlight at medical conferences as MSA clinical research moves toward phase III planning
Presentations at key medical conferences in May support advancement of Alterity’s lead drug ATH434 into Phase III development for Multiple ... Read More The post Alterity in spotlight at medical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results